Qianhong Bio-pharma(SZ:002550) Xin Lang Zheng Quan·2025-10-31 16:42Core Viewpoint - Qianhong Pharmaceutical is a leading enterprise in the biopharmaceutical sector in China, focusing on drug research, production, and sales, with a full industry chain advantage and multiple core technologies [1] Group 1: Business Performance - In Q3 2025, Qianhong Pharmaceutical achieved a revenue of 1.215 billion yuan, ranking 45th among 110 companies in the industry, significantly lower than the top companies, East China Pharmaceutical at 32.664 billion yuan and Fosun Pharmaceutical at 29.393 billion yuan [2] - The net profit for the same period was 368 million yuan, ranking 25th in the industry, with the top company, Heng Rui Medicine, reporting 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Qianhong Pharmaceutical's debt-to-asset ratio was 8.48%, down from 10.04% year-on-year and significantly lower than the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for the same period was 57.71%, higher than the previous year's 54.02% and above the industry average of 57.17%, reflecting strong profitability [3] Group 3: Leadership and Compensation - The chairman, Wang Yaofang, has a salary of 369,500 yuan in 2023, while the general manager, Wang Ke, has a salary of 1.2873 million yuan, a slight decrease from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 1.17% to 73,600, with an average holding of 12,800 circulating A-shares, a decrease of 1.15% [5] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 49.0352 million shares, an increase of 19.8701 million shares from the previous period [5] Group 5: Future Outlook - In H1 2025, Qianhong Pharmaceutical reported a revenue of 862 million yuan, a year-on-year increase of 0.72%, and a net profit of 258 million yuan, up 41.17% [5] - The company has four innovative drugs in phase II clinical trials or about to enter phase III, indicating a strong innovation pipeline [6] - Revenue forecasts for 2025-2027 are adjusted to 1.749 billion, 2.091 billion, and 2.500 billion yuan, with net profit forecasts of 459 million, 423 million, and 475 million yuan respectively [5][6]